Mursla Bio
PrivateLast Round
Convertible Debt
Sep 1, 2020
Total Funding Raised
$602,000
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Mursla Bio is a biotechnology company developing a non-invasive diagnostic platform for the early detection of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical AI, Drug Discovery, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Revenue Share, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mursla Bio Comparables
Compare Mursla Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Helio Genomics | 84% | |
| Mercy BioAnalytics | 83% | |
| Glycotest, Inc. | 82% |
Mursla Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Sep 1, 2020 | ||||
| Grant | Sep 1, 2020 |
Mursla Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Future Fund | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Monthly visitors increased 99% MoM.
- Mar 26, 2026
Joined the ABHI US Accelerator program to support US market entry.
Mursla Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access